LIST OF TABLES

Table No.	Title	Page No.
2.1	Differences between emulsions and microemulsions	49
2.2	Rationale for developing and using medicated microemulsions	49
3.1	Materials and equipments- Analytical methods	83
3.2	Calibration of nicergoline in acetonitrile	86
3.3	Evaluation of accuracy and precision of the estimation method of nicergoline in acetonitrile	87
3.4	Calibration of nicergoline in methanol	89
3.5	Evaluation of accuracy and precision of the estimation method of nicergoline in methanol	90
3.6	Calibration of sibutramine base in acetonitrile	92
3.7	Evaluation of accuracy and precision of the estimation method of sibutramine base in acetonitrile	93
3.8	Calibration of sibutramine base in methanol	95
3.9	Evaluation of accuracy and precision of the estimation method of sibutramine base in methanol	95
3.10	Calibration of hydergine in acetonitrile	98
3.11	Evaluation of accuracy and precision of the estimation method of hydergine in acetonitrile	98
3.12	Calibration of hydergine in methanol	100
3.13	Evaluation of accuracy and precision of the estimation method of hydergine in methanol	101
3.14	Calibration of PE-mAb-Tfr in PBS pH 7.4	103
3.15	Evaluation of accuracy and precision of the estimation method of PE-mAb-Tfr in PBS pH 7.4	105
4.1	Materials and equipments- Preparation, antibody conjugation and characterization of nanoparticles	113
4.2	Gas chromatography coupled with static headspace operating parameters	125
4.3	Optimization of rate of addition of organic phase	126
4.4	Influence of stirring speed	126
4.5	Optimization of probe sonication time	126
4.6	Influence of stirring time	126
4.7	3^3 factorial experimental design for NG nanoaprticles	127
4.8	3^3 factorial experimental design for HG nanoaprticles	127
4.9	3^3 factorial experimental design for SB nanoaprticles	128
4.10	Analysis of variance of full and reduced model for NNp	129
4.11	Analysis of variance of full and reduced model for HNp	129
4.12	Analysis of variance of full and reduced model for SNp	130

4.13	Check point analysis for NNp	136
4.14	Check point analysis for HNp	137
4.15	Check point analysis for SNp	137
4.16	Effect of different cryoprotectants on the particle size and redispersion of NG nanoparticles	137
4.17	Optimization of antibody conjugation activation pH	138
4.18	Optimization of antibody conjugation reaction temperature	138
4.19	Optimization of amount of activating agent	138
4.20	Optimization of antibody conjugation reaction time	138
4.21	Optimization of amount of antibody	138
4.22	Characterization of optimized drug containing nanoparticles	139
4.23	In-vitro diffusion study data for drug containing formulations	142
4.24	Stability study data of nicergoline nanoparticles	145
4.25	Stability data of hydergine nanoparticles	146
4.26	Stability data of sibutramine nanoparticles	147
5.1	Materials and equipments-Preparation, optimization and characterization of microemulsions	168
5.2	Drug solubility study data	178
5.3	Effect of process parameters on the globule size and zeta potential of NG microemulsions	178
5.4	Effect of dilution on globule size and zeta potential of NG microemulsion	178
5.5	3^2 Factorial design for optimization of nicergoline microemulsion	180
5.6	3^2 Factorial design for optimization of hydergine microemulsion	180
5.7	3^2 Factorial design for optimization of sibutramine microemulsion	180
5.8	Analysis of variance of full and reduced model for NME	181
5.9	Analysis of variance of full and reduced model for HME	181
5.10	Analysis of variance of full and reduced model for SME	182
5.11	Checkpoint batches for nicergoline microemulsions	184
5.12	Checkpoint batches for hydergine microemulsions	185
5.13	Checkpoint batches for sibutramine microemulsions	185
5.14	Composition and characterization of drug containing microemulsions	185
5.15	*In-vitro* release study data for drug containing microemulsions	189
5.16	*In-vitro* diffusion study data for drug containing microemulsions	190
5.17	Results of stability study	191
6.1	Influence of incubation time and amount of stannous chloride on the radiolabeling efficiency of nicergoline formulations	212
6.2	In vitro stability of ^{99m}Tc labeled nicergoline formulations in 0.9%w/v sodium chloride and rat serum at 37°C	212
6.3	Compartmental distribution of ^{99m}Tc-labeled nicergoline formulations at predetermined time intervals in balb/C mice	213

6.4	Compartmental distribution of ^{99m}Tc-labeled hydergine formulations at predetermined time intervals in balb/C mice	215
6.5	Compartmental distribution of ^{99m}Tc-labeled sibutramine formulations at predetermined time intervals in balb/C mice*	216
6.6	Pharmacokinetics of ^{99m}Tc labeled NG formulations at predetermined time intervals in balb/C mice*	220
6.7	Pharmacokinetics of ^{99m}Tc labeled HG formulations at predetermined time intervals in balb/C mice*	221
6.8	Pharmacokinetics of ^{99m}Tc labeled SB formulations at predetermined time intervals in balb/C mice*	222
6.9	Drug targeting index and direct brain drug targeting percentage following intranasal administration of NG, HG and SB formulations	223
7.1	Composition of high fat diet given to animals to induce obesity	238
7.2	Obesity induction: weight and serum lipid profile of animals at initiation and end (10 weeks) of high fat diet feeding period	238
7.3	Anti-obesity activity: body weight, serum lipids, serum leptin and white adipose tissue mass of animals at the end of drug treatment period (45 days)	238
7.4	Brain infarct volume, ratio of hemisphere areas, glutathione estimated for anti-ischemic activity	239